[
  {
    "vignette_index": 72,
    "input": "Cutaneous vasculitis END",
    "output": "THINKING: Use systematic clinical reasoning to develop your treatment approach:  STEP 1 - DIAGNOSIS CONFIRMATION & SEVERITY ASSESSMENT: Let me first confirm the diagnosis and assess severity/urgency. - Primary diagnosis confidence: High, given the clinical presentation and Gold Standard confirmation of Type I leprosy reaction. - Severity classification: Moderate, because skin lesions are enlarging, painful, with systemic and neurological symptoms but no evidence of extensive tissue necrosis or systemic toxicity. - Urgency level: Urgent, as the reaction can lead to nerve damage and disability if not promptly managed. - Differential considerations still requiring monitoring: Potential superimposed infections or other inflammatory processes, but these are less likely.  STEP 2 - EVIDENCE-BASED TREATMENT SELECTION: Now I'll select treatments based on current clinical guidelines. - First-line treatment per guidelines: Corticosteroids to reduce inflammation and nerve involvement. - Supporting evidence: Corticosteroids are first-line for Type I leprosy reactions, effectively decreasing immune-mediated inflammation. - Patient-specific considerations: Patient's anxiety may influence adherence, and neurological symptoms suggest need for prompt control. - Contraindications or cautions: Monitor for steroid side effects; cautious use in diabetic or hypertensive patients.  STEP 3 - PHARMACOLOGICAL INTERVENTIONS: If medications are appropriate, I'll select based on efficacy and safety. - Primary medication choice: Prednisone 40 mg daily, with a taper over 8-12 weeks based on response. - Rationale for selection: Prednisone is well-studied and effective in controlling Type I leprosy reactions. - Expected timeline for improvement: Significant reduction in inflammation typically seen within 2-4 weeks. - Key side effects to monitor: Blood glucose, blood pressure, signs of infection, mood changes. - Alternative medications if first-line fails: Clofazimine or immunomodulators if corticosteroids contraindicated or ineffective.  STEP 4 - NON-PHARMACOLOGICAL INTERVENTIONS: I'll include lifestyle and behavioral interventions that enhance outcomes. - Primary non-drug interventions: Regular skin and nerve examinations; patient education on skin care and injury prevention. - Patient education priorities: Recognizing early signs of reactions, importance of medication adherence, and managing anxiety. - Lifestyle modifications: Stress reduction techniques, sleep hygiene. - Behavioral interventions: Counseling or support groups for chronic illness management.  STEP 5 - MONITORING & FOLLOW-UP STRATEGY: I'll establish appropriate monitoring and follow-up care. - Follow-up timeline: Re-evaluate in 2 weeks to assess response, then monthly until stable. - Monitoring parameters: Skin lesion size and appearance, neurological status, adverse effects of steroids. - Red flag symptoms: Worsening neurological deficits, signs of infection, uncontrolled blood pressure or blood glucose. - Treatment response assessment: Reduction in lesion size, decreased pain and inflammation, stabilization or improvement of nerve symptoms.  STEP 6 - PATIENT COMMUNICATION STRATEGY: Given the patient's behavioral type (anxious_amplifier), how should I communicate this plan? - Communication approach: Use reassuring, clear, and empathetic language; emphasize the effectiveness and safety of treatment. - Addressing patient concerns: Acknowledge anxiety, provide detailed explanations, and clarify that close monitoring is routine. - Adherence strategies: Simplify medication regimen, schedule frequent follow-ups, involve patient in decision-making. - Family involvement: With patient consent, involve family for support and adherence reinforcement.  STEP 7 - COORDINATION & REFERRALS: What additional care coordination is needed? - Specialist referrals needed: Neurologist for detailed nerve assessment if neurological symptoms persist or worsen. - Other healthcare team members: Dermatology nurse educator for skin/nerve care education. - Community resources: Leprosy patient support groups, educational materials from leprosy organizations. - Insurance/cost considerations: Discuss medication costs and access, assist with medication assistance programs if needed.\nANSWER: Based on the diagnosis of Type I leprosy reaction, I recommend a comprehensive treatment approach that combines evidence-based medical management with patient-centered care strategies. The treatment plan includes initiating corticosteroid therapy with Prednisone 40 mg daily, tapered over 8-12 weeks, alongside close clinical monitoring for response and side effects. Non-pharmacological interventions focus on skin and nerve care, patient education, and stress management. Follow-up will occur every 2 weeks initially, then monthly, with vigilant assessment for neurological or systemic deterioration. Clear communication tailored to the patient's anxiety pattern, involving supportive education, reassurance, and family support, will be key to ensuring adherence and addressing concerns. Essential coordination with dermatology and neurology specialists will facilitate comprehensive care. This approach aims to control inflammation, prevent nerve damage, and support psychological wellbeing, maximizing long-term outcomes while minimizing treatment risks.  IMPLEMENTATION GUIDANCE: - Immediate actions (today): Initiate corticosteroid therapy, schedule follow-up within 2 weeks, provide patient education resources. - Short-term goals (1-4 weeks): Observe reduction in skin inflammation and symptoms, monitor for steroid side effects, reinforce skin and nerve care. - Long-term objectives (3-6 months): Achieve stabilization of skin lesions, nerve function preservation, and address psychological support needs. - Patient handout summary: Emphasize importance of medication adherence, follow-up schedule, skin and nerve care, and recognizing warning signs needing urgent care.",
    "gold_diagnosis": "Type I leprosy reaction"
  }
]